Wegovy in Barcelona: Weight Loss with Comprehensive Monitoring

Wegovy: The Semaglutide Formulation Designed to Treat Obesity

Wegovy is the brand name for semaglutide in a specific formulation and dosage for the treatment of obesity and overweight with comorbidities. The molecule is the same as Ozempic, but the indication and dosing schedule are different: while Ozempic is primarily authorized for type 2 diabetes, Wegovy is designed and authorized for medically supervised weight loss.

It is a highly effective drug, with solid clinical data in patients with obesity. But its responsible use requires three things: correct indication, progressive dose titration, and medical-nutritional monitoring. At Santé Clinics, we integrate all three elements into a unique protocol. This article explains what it is, how it works, for whom it is indicated, and how we implement it.

What is Wegovy and How Does It Work

Wegovy is semaglutide, a GLP-1 receptor agonist. It mimics the action of glucagon-like peptide-1, a natural intestinal hormone that the body releases after eating. By activating the GLP-1 receptor, it:

• Increases feelings of satiety through signaling in the hypothalamus and brainstem.
• Slows gastric emptying: meals “fill you up” for longer.
• Stimulates glucose-dependent insulin secretion.
• Reduces glucagon secretion.
• Decreases appetite and cravings, including the “hedonic” or impulsive component of eating.

The net effect is a significant reduction in spontaneous caloric intake and, with it, clinically significant weight loss.

It is administered via subcutaneous injection, once a week, with progressive dose titration over several weeks to improve digestive tolerance.

Documented Benefits

In the pivotal STEP-1 trial and subsequent studies, obese patients treated with semaglutide 2.4 mg weekly plus lifestyle intervention achieved average weight losses of around 15% of body weight at 68 weeks, with significant percentages of patients reaching >20%. Beyond weight:

• Improvement in glycemic profile (in patients with prediabetes and type 2 diabetes).
• Improvement in lipid profile.
• Reduction in blood pressure.
• Improvement in hepatic markers and quality of life.
• Reduction in cardiovascular risk in high-risk populations, according to specific studies.

The benefits depend on adherence, the tolerated dose, and, above all, nutritional and exercise support.

Indications

Wegovy is indicated, in its main regulatory approvals, for adults with:

• Obesity (BMI ≥30).
• Overweight (BMI ≥27) with at least one associated comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, established cardiovascular disease).

In conjunction with a hypocaloric diet and increased physical activity. The latter is not merely decorative; the drug was approved accompanied by lifestyle changes, not as an isolated treatment.

It is not indicated:

• In patients with normal weight or overweight without comorbidities.
• As an aesthetic treatment for “definition” or losing the last few pounds.
• Pregnancy, lactation, short-term pregnancy planning.
• Personal or family history of medullary thyroid carcinoma or MEN-2.
• History of severe pancreatitis.
• Hypersensitivity to the active substance.

Common Side Effects

The most frequent are digestive and, for the most part, dose-dependent and reversible:

• Nausea (in the first few weeks and when increasing doses).
• Diarrhea, constipation.
• Fullness, reflux, belching.
• Mild abdominal pain.
• Headache, transient fatigue.
• Decreased appetite (desired effect, but it is advisable to ensure protein and micronutrient intake).

They usually improve with proper titration and nutritional adjustments.

Less frequent but relevant adverse events:

• Acute pancreatitis: in case of severe abdominal pain, discontinue and consult.
• Cholelithiasis and biliary disease.
• Hypoglycemia if combined with insulin or sulfonylureas.
• Allergic reactions.
• Transient worsening of retinopathy in diabetics with previously poor glycemic control.

How the Wegovy Protocol is at Santé Clinics

1. Initial medical consultation: complete clinical history, personal and family history, medication, comorbidities, examination, blood pressure, BMI, abdominal circumference, recent or requested lab tests.
2. Assessment of indication and exclusion of contraindications.
3. Nutritional consultation (mandatory): plan design, protein intake, digestive management, hydration, exercise plan.
4. Start of treatment with progressive weekly titration according to clinical guidelines.
5. Monthly monitoring in the initial phases (tolerance, dose adjustment, weight evolution, body composition with bioimpedance).
6. Coordination with body aesthetic devices if sagging or redistribution appears (HIFU, INDIBA, mesotherapy, collagen stimulators).
7. Maintenance plan and periodic re-evaluation.

The Inevitable Question: Is It Forever?

Obesity is a chronic disease with a biological basis. This means that many patients require long-term sustained treatment, just like a patient with hypertension or dyslipidemia.

Some patients:

• Can maintain results after discontinuing the drug if they have established habits.
• Require low-dose maintenance indefinitely.
• Require treatment cycles.

The evolution decides, not a fixed expectation. What is a rule: discontinuing the drug without having worked on nutrition and exercise is associated with weight regain.

Wegovy vs Ozempic vs Mounjaro

• Ozempic: semaglutide, primary indication type 2 diabetes.
• Wegovy: semaglutide in specific formulation and dose for obesity.
• Mounjaro / Zepbound: tirzepatide, dual GIP/GLP-1 agonist.

The choice is made by the physician based on the patient, indication, comorbidities, availability, and response. It is not “better or worse” in the abstract.

What GLP-1 Alone Does Not Do

• It does not build muscle mass: protein + strength training does.
• It does not educate habits: the nutritionist and time do.
• It does not correct sagging that may appear with significant weight loss: body aesthetic devices are for that.

Frequently Asked Questions

Is Wegovy the same as Ozempic? The active ingredient is the same (semaglutide), but the presentation, dosage, and official indication are different. Wegovy is specifically designed to treat obesity.

Is the medical consultation to assess treatment free? No. It is a specialized medical consultation with its cost; we confirm it upon booking.

How much weight is lost with Wegovy? In pivotal studies, around 15% of body weight at 68 weeks with maximum dose and lifestyle support, with variability per patient.

Do I have to inject myself? Yes, it is a weekly subcutaneous autoinjector pen that the patient learns to use.

What if I tolerate it poorly? Titration is adjusted to the patient. Nutritional strategies exist, and if necessary, other drugs can be considered.

Do I need to exercise? It is highly recommended. Strength training is essential to preserve muscle mass during weight loss.

Book Your Medical Assessment for Wegovy at Santé Clinics

The first step is not the injection. It is an honest medical consultation to decide if it is the right tool for you and, if so, to integrate it into a plan that combines nutrition, exercise, and, when appropriate, body aesthetic devices.

Make an appointment via WhatsApp at +34 699 14 58 87. Avenida Diagonal 384, Barcelona.